Wednesday, July 26, 2017 10:10:58 AM
“The company anticipates filing an investigational device exemption (IDE) supplement to add an interim efficacy readout in the fourth quarter of 2018 and expects top line data in the fourth quarter of 2019.”
Tweet this
The investigational CardiAMP cell therapy system is designed to deliver a high dose of a patient’s own bone marrow cells directly to the region of cardiac dysfunction to stimulate the body’s natural healing mechanism after a heart attack. Patients are selected for the investigational treatment, in part, based on biomarkers in their bone marrow that are anticipated to maximize the potential for patient benefit.
“Leading clinical sites are actively screening patients for the randomized phase of our Phase III trial, and we are onboarding additional clinical sites in the United States,” stated BioCardia Chief Medical Officer Eric Duckers, MD, PhD, FESC. “The company anticipates filing an investigational device exemption (IDE) supplement to add an interim efficacy readout in the fourth quarter of 2018 and expects top line data in the fourth quarter of 2019.”
The CardiAMP Heart Failure Trial is a Phase III, multi-center, randomized, double-blinded, sham-controlled study of up to 260 patients at 40 centers nationwide, which includes a 10-patient roll-in cohort. The trial’s primary endpoint is an improvement in six minute walking distance at 12 months post-treatment. In addition, the primary endpoint analysis incorporates the impact of major adverse cardiac events and other clinically meaningful events.
The company reaffirms guidance on its IDE submission in calendar year 2017 for a new CardiAMP indication to treat patients post-myocardial infarction. In addition, the company anticipates submitting an investigational new drug (IND) application in calendar year 2018 for CardiALLO cell therapy, which utilizes bone marrow-derived mesenchymal cells from a donor to treat heart failure.
http://www.businesswire.com/news/home/20170726005489/en/BioCardia-Completes-Roll-in-Cohort-Pivotal-Phase-III
Recent BCDA News
- BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort • GlobeNewswire Inc. • 04/25/2024 01:00:00 PM
- BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results • GlobeNewswire Inc. • 03/27/2024 08:00:00 PM
- BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership • GlobeNewswire Inc. • 03/13/2024 11:00:00 AM
- BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study • GlobeNewswire Inc. • 03/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 01:00:21 PM
- BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/27/2024 09:53:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 12:00:19 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 10:06:32 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/14/2024 09:17:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 02:58:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 12:03:57 PM
- BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:28:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 07:06:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 12:00:22 PM
- BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 12:00:18 PM
- BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 12:00:27 PM
- BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction • GlobeNewswire Inc. • 12/19/2023 12:00:00 PM
- BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes • GlobeNewswire Inc. • 12/18/2023 12:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 12:00:30 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM